ADAR2 is selectively downregulated in CBF AMLs. (A) Box plots showing the expression levels of ADAR1, ADAR2, and ADAR3 in healthy donors (n = 8) and patients with different subtypes of AML (n = 108) (∗∗∗∗P < .0001, 2-tailed Student t test) detected by microarray. The data were obtained from Gene Expression Omnibus database (GSE1159).³¹ The expression level of a particular gene is reflected by the intensity of hybridization of labeled mRNA to gene-specific probe sets (10-20 oligonucleotides per gene).³¹ The line in the middle of the box is plotted at the median. The whiskers indicate minimum to maximum. (B) Box plots showing the expression of ADAR1, ADAR2, and ADAR3 in patients with t(8;21) AML (n = 7) and control patients with non-CBF (n = 164) AML from the TCGA AML RNA-seq data sets. (C) Box plot showing the relative expression of ADAR2 in leukemic blasts isolated from patients with AML with t(8;21) (n = 11) or normal karyotype (n = 13) and CD34⁺ cells isolated from BM samples of healthy individuals (n = 16). The relative expression was calculated as described in supplemental Materials and Methods. Data are presented as technical triplicates from a representative experiment. ∗∗P < .01; ∗∗∗∗P < .0001 using two-tailed Student t test. chr, chromosome; ns, not significant.